• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock

This biotech is on the front lines of oncology treatments.
By BRUCE KAMICH
May 04, 2020 | 11:45 AM EDT
Stocks quotes in this article: SGEN

On Mad Money Friday night, Jim Cramer checked in Dr. Clay Siegall, chairman and CEO of Seattle Genetics Inc. (SGEN) , a biotech on the front lines of oncology.

Siegall said their drug for metastatic bladder cancer is in its first full quarter of sales and doctors are embracing it as the leading treatment. The company continues clinical trials both in the U.S. and globally to see the drug used as front-line treatments.

Siegall was also bullish on Tukysa, the company's breast cancer treatment, which received FDA approval this month for advanced-stage HER2-positive breast cancer.

Let's check out the charts of SGEN.

In the daily bar chart of SGEN, below, we can see that prices have performed strongly in the past 12 months. Prices made a base pattern around the $70 level and then another upper level base pattern around $120. Prices are above the rising 50-day moving average line and the rising 200-day moving average line.

The daily On-Balance-Volume (OBV) line made only a small dip from February to March, which is similar to the modest decline in prices this February/March. The OBV line has firmed since late March and is not far from making a new high for the move up. A rising OBV line tells us that buyers of a stock have been more aggressive than sellers.

The trend-following Moving Average Convergence Divergence (MACD) oscillator is well above the zero line in bullish territory. This indicator has narrowed significantly but renewed price strength may keep the MACD oscillator from crossing to a take profits sell signal.

In the first weekly bar chart of SGEN, below, we can see a long consolidation pattern/base pattern around the $70 or $60 area. Prices have rallied from that base to double. A triple from the base is the next price target -- the $180-$210 area. The 40-week moving average line is below the price action and in a bullish or positive slope.

The weekly OBV line shows a long rise and is not far from making a new high for the move up. The MACD oscillator is above the zero line and just crossed to another buy signal.

In this second weekly bar chart of SGEN, below, we wanted to show more price history to expand on the size of the base around $60. The base is more than two years in duration and has allowed for a lot of accumulation (buying). A triple from this base may not be bullish enough.

In this first Point and Figure chart of SGEN, below, we used daily price data and here SGEN has met its upside price target.

In this second Point and Figure chart of SGEN, below, we used weekly price data. Here the chart shows $286 as a potential longer-term price target.

Bottom-line strategy: The business of finding blockbuster cancer drugs can be feast or famine but it looks like SGEN is doing it right. Trade SGEN from the long side risking a close below $135 for now. We have prices targets from $180 on up to $286.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Pharmaceuticals | Mad Money | Executive Interview

More from Stocks

SoFi Technologies Is Primed for a Rebound

Bruce Kamich
May 16, 2022 8:50 AM EDT

Here's where the shares may be headed next.

Don't Worry About Capitulation but Focus on How the Market Wind Is Blowing

Bob Byrne
May 16, 2022 8:17 AM EDT

If you're a short-term trader, try to identify which way the market is trying to auction.

My Review of Indicators Points the Way to a Tradable Rally

Bruce Kamich
May 16, 2022 7:58 AM EDT

Keep in mind that this is not a buy-and-hold recommendation but rather a path to producing modest gains over the next few weeks.

Worries About a Potential Recession Are Building

James "Rev Shark" DePorre
May 16, 2022 7:39 AM EDT

For now, this is a bear market, and strength cannot be trusted.

Markets, Not So Confident Fed, Stocks Losing Streak, China Economy, My Trades

Stephen Guilfoyle
May 16, 2022 7:18 AM EDT

This week's earnings focus will be on the retailers with rivals such as Walmart and Target, as well as Home Depot and Lowe's reporting.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login